PAR-25-074: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) (PAR-28-042). Status: Due dates in the notice, expires November 16, 2029. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 14, 2026.
From the official notice on Grants.gov, last changed October 15, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUH2 / UH3
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$263,670
- Typical project length2 years
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under PAR-25-074 were run by National Cancer Institute (NCI, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-074 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-28-042 | November 3, 2026 | Due dates in the notice, expires November 16, 2029 | Open |
| PAR-23-313 | November 1, 2023 | Closed October 15, 2024 | Closed |
Key dates
| Posted | October 15, 2024 |
|---|---|
| Deadline | October 14, 2026 |
| Archived by Grants.gov | November 19, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (61% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.
Funded under PAR-25-074 so far
NIH funded 5 projects under PAR-25-074 in fiscal 2026, at 5 institutions. The median yearly award was $263,670.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A multimodal liquid biopsy assay to quantify androgen receptor’s somatic alterations in metastatic castration-resistant prostate cancer. | H. Lee Moffitt Cancer Ctr & Res Inst | 2026 | $225,511 |
| Validation of a Liquid Biopsy Assay for Early Detection of Lymphoma in People with HIV | Yale University | 2026 | $279,018 |
| Transcriptomic molecular risk classification for children with B cell acute lymphoblastic leukemia | Children's Hosp of Philadelphia | 2026 | $350,860 |
| Validation of a Dysplasia Grading Assay for Precancerous Pancreatic Cystic Lesions | Amplified Sciences Inc | 2026 | $182,018 |
| Clinical Translation of a Urine-Based Biomarker for the Detection of Residual Disease in Radical Cystectomy Candidates | Research Inst of Fox Chase Can Ctr | 2026 | $263,670 |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-28-042, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-074 still open?
No. It closed on October 14, 2026. A newer notice is open: PAR-28-042, due dates in the notice, expires November 16, 2029.
Who can apply for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
Closed October 14, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-25-074?
NIH RePORTER lists 5 projects funded under PAR-25-074 in fiscal 2026, at 5 institutions. The most were at H. Lee Moffitt Cancer Ctr & Res Inst, Yale University, Children's Hosp of Philadelphia.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)